AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KNOV 42 min read$BCRX

BioCryst Reports Third Quarter 2026 Financial Results

BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioCryst Reports Third Quarter 2026 Financial Results — Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenu

Original reporting
SEC EDGAR 8-K
Published Nov 4, 2026, 12:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BCRX
Bullish
high confidence
Mentioned
$BCRX
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$BCRXBullishHigh
01

Why it matters

The raised revenue outlook and strong operating profit indicate momentum, likely prompting buying interest.

02

Market read

Earnings beat and raised guidance provide a clear catalyst for BCRX, making the article highly relevant for traders.

03

What to watch

Potential cost of Birmingham site closure and R&D spend could pressure margins.

Relevance 7/10Novelty 9/10Timing: after-hours release

Background

BioCryst filed an 8‑K reporting its third‑quarter financials and updated guidance.

Company-level read

Ticker impact

$BCRXBullishHigh confidence
Context

BioCryst disclosed Q3 2026 results with $180.3M revenue and raised total revenue guidance to $715M-$730M.

Expected impact

likely upward pressure as investors price in higher revenue outlook

Evidence & confidence

The company reported stronger-than-expected revenue and increased full-year revenue guidance, which typically supports a price rally.

Market effects

Sector

Boosts sentiment for rare‑disease biotech sector as a peer shows strong growth.

Regional

May lift US biotech indices in the short term.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If guidance is overly optimistic, the stock could face disappointment on future quarters.

Key entities

  • company
    BioCryst Pharmaceuticals, Inc.

    US‑listed biotech focused on rare‑disease therapeutics.

Read at source← All news

Related articles

NOV 4
$BCRXMedAI 8/10

BioCryst (BCRX) Q3 2026 Earnings Call Transcript

BioCryst (BCRX) reported Q3 2026 earnings, highlighting growth in ORLADEYO pellet usage among children and a transition to CareMed as their sole pharmacy partner. The company expects to announce top-line data for navenibart in Q3 2027 and is on track to share early clinical data for BCX1771 by year-end. Revenue was $174.8 million, with ORLADEYO revenue increasing 20% year-over-year. The company anticipates continued revenue growth and cost savings in 2027.

finance.yahoo.com7 min
NOV 4
$BCRXHighAI 8/10

BioCryst Q3 2026 slides: HAE portfolio drives 70% profit jump

BioCryst Pharmaceuticals (BCRX) reported Q3 2026 non-GAAP operating profit of $87M, up 70% YoY, driven by ORLADEYO revenue of $175M. The company raised full-year 2026 revenue guidance to $715M-$730M. ORLADEYO showed 91% reduction in monthly attack rate for HAE patients. Navenibart, a potential second HAE treatment, is in Phase 3 trials with data expected in Q3 2027. BioCryst also highlighted its pipeline, including BCX17725 for Netherton syndrome.

investing.com3 min
NOV 4
$BCRXHighAI 8/10

BioCryst Pharmaceuticals Q3 Earnings Call Highlights

BioCryst Pharmaceuticals reported Q3 non-GAAP net income of $71M, up from last year. The company launched ORLADEYO pellets for children and plans to introduce a 150-mg pellet formulation. Pediatric uptake is ahead of expectations. BioCryst maintained 2026 ORLADEYO revenue guidance of $625M-$645M but raised total revenue guidance to $715M-$730M. The company is also progressing with its navenibart trial for HAE and BCX17725 study for Netherton syndrome.

finance.yahoo.com2 min
NOV 4
$BCRXMedAI 8/10

BioCryst: Q3 Earnings Snapshot

BioCryst Pharmaceuticals reported Q3 earnings of $37.9M, or 14 cents per share, exceeding expectations. Revenue was $180.3M, also above forecasts. The company expects full-year revenue between $715M and $730M. Shares are up 10% YTD and 25% over the past year.

finance.yahoo.com2 min
OCT 22
$BCRXHighAI 9/10

FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE

BioCryst Pharmaceuticals announced FDA approval of a 150 mg oral pellet formulation of berotralstat (Orladeyo) for HAE prophylaxis in patients aged 12+. The approval adds a second dosage form, following prior approvals for capsules and pediatric pellets. BioCryst reports berotralstat is the only targeted oral prophylactic therapy for HAE patients aged 2+.

hcplive.com2 min